Bristol Myers Squibb gets European Commission nod for Opdivo plus Yervoy for Hepatocellular Carcinoma Ruchika Sharma9 March 2025 12:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus Yervoy (ipilimumab) for the...
Bristol Myers Squibb application for Opdivo Plus Yervoy for MSI-H/ dMMR colorectal cancer accepted by USFDA Ruchika Sharma27 Feb 2025 12:46 PM ISTBristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental biologics license application...
Injectable version of Bristol Myers Squibb cancer drug Opdivo gets USFDA okay Ruchika Sharma28 Dec 2024 12:30 PM ISTOpdivo Qvantig offers a faster delivery for patients to receive this immunotherapy treatment option in three to five minutes compared to 30 minute IV...
Bristol Myers Squibb gets European Commission nod for Opdivo plus Yervoy to treat colorectal cancer Ruchika Sharma25 Dec 2024 4:52 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Commission (EC) has approved Opdivo (nivolumab) plus...
Bristol Myers Squibb gets positive CHMP opinion for Opdivo plus Yervoy to treat adult with MSI-H or dMMR metastatic Colorectal Cancer Ruchika Sharma18 Nov 2024 4:57 PM ISTPrinceton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines...
USFDA accepts application for Opdivo plus Yervoy for unresectable hepatocellular carcinoma Ruchika Sharma22 Aug 2024 4:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the U.S. Food and Drug Administration (FDA) has accepted the supplemental Biologics License...
Bristol Myers Squibb gets EMA validation of application for Opdivo plus Yervoy for Hepatocellular Carcinoma Ruchika Sharma21 July 2024 3:30 PM ISTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated its Type II variation application for...
Bristol Myers Squibb application for subcutaneous Nivolumab validated by EMA Ruchika Sharma23 Jun 2024 10:00 AM ISTPrinceton: Bristol Myers Squibb has announced that the European Medicines Agency (EMA) has validated the extension application to introduce...
Immunotherapy drug combination helps extend survival in patients with metastatic melanoma Dr. Kamal Kant Kohli22 Aug 2023 9:45 AM ISTUSA: An immunotherapy drug combination was shown to be an effective second-line therapy for metastatic melanoma, an aggressive and deadly type of...
Medical Bulletin 13/September/2022 Isra Zaman13 Sept 2022 12:07 PM ISTHere are the top medical news for the day:Immunotherapy before surgery helpful for common skin cancer patients: StudyIn an international, multicenter...
Novel combination immunotherapy for patients with metastatic colorectal cancer Isra Zaman13 Sept 2022 9:45 AM ISTA physician-scientist at City of Hope, has identified a novel combination immunotherapy regimen that demonstrated significant response in a subgroup...
Nivolumab combo with chemotherapy or ipilimumab prolongs survival in Advanced esophageal carcinoma Dr. Kamal Kant Kohli8 Aug 2022 8:00 PM ISTNivolumab has recently been approved both in combination with fluoropyrimidine-and platinum-based combination chemotherapy and in combination with...
